Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03553875Phase 3Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2018
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Autism Spectrum Disorder (ASD) and Nonverbal Learning Disorder (NVLD) comparing Memantine with Placebo (2 arms). Primary endpoint: Clinical Global Impression-Improvement Scale at 12 weeks. Started Nov 2018; status: terminated.
02
Drugs
memantine
03
Conditions
Autism Spectrum Disorder (ASD)Nonverbal Learning Disorder (NVLD)
Beyond the preview
Go deeper on NCT03553875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03553875.